CancerRadarCancerRadar
Tyrosine kinase inhibitorFDA-approvedSecond-line

Lapatinib

How it works

Blocks the HER2 and EGFR receptors on cancer cells, preventing growth signals and inhibiting cell division.

Cancer types

Breast Cancer— HER2-positive
Pancreatic Cancer— HER2-positive
Ovarian Cancer— HER2-positive

Efficacy

Clinical trials have shown that lapatinib can improve progression-free survival in HER2-positive patients who have received prior therapy.

Side effects

Moderate

Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.

Evidence from research

StudyCancer typeStageEfficacy
Understanding Lapatinib Resistance in HER2+ Breast CancerBreast Cancerlab-study—Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.